Home > D. General pathology > Therapy, Toxics and drugs > sorafenib
sorafenib
Tuesday 2 June 2009
Nexavar
| WP |
Definition: Sorafenib is a small molecular inhibitor of several protein kinases (multikinase inhibitor).
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Protein kinases are overactive in many of the molecular pathways include Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 and 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways.
Sorafenib is unique in targeting the Raf/Mek/Erk pathway.
Indications
primary kidney cancer (advanced renal cell carcinoma)
advanced primary liver cancer (hepatocellular carcinoma)
hepatoblastoma and recurrent hepatoblastoma
malignant epithelioid hemangioendothelioma of the liver (22826791)
Sorafenib (Nexavar, Bayer), is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Treatment with sorafenib led to a potent inhibition of cell viability, tumour progression and angiogenesis in hepatoblastoma. Sorafenib might therefore also be a promising treatment option for high risk or recurrent hepatoblastoma. (22176637)
Links